{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "DecreaseAmount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q64896",
      "entity_text" : "HBeAg",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0923" ],
      "Species" : [ "taxonomy:10407" ]
    }
  },
  "verbose_text" : "It is commonly recognized that in HBeAg positive patients the loss of HBeAg and the development of anti-HBe sustained for consecutive 12 months of therapy at normal ALT levels and viraemia below 2,000 IU/ml may justify the cessation of treatment.",
  "reading_complete" : "2020-08-03T18:26:01Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T18:20:40Z",
  "trigger" : "loss",
  "evidence" : [ "loss of HBeAg" ],
  "pmc_id" : "5497479",
  "score" : 0
}